Study wrapper · #874
Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Editor's note
This pharmacovigilance study mines the FAERS database for real-world tirzepatide safety signals and benchmarks them against semaglutide. Disproportionality analyses flag associations, not incidence or causation, so novel signals like starvation ketoacidosis are hypothesis-generating rather than confirmed. Useful safety context for readers, provided the reporting-bias caveat is kept front and center.
Plain-language abstract
A large analysis of FDA adverse-event reports found the most common tirzepatide safety signals were medication errors, injection-site reactions, and gastrointestinal issues, with most events reported within the first month. Compared with semaglutide, tirzepatide had lower reported odds of vomiting, constipation, and decreased appetite.